Worried About the Market? These Stocks Have a Track Record of Helping Investors Sleep at Night.

The article highlights J&J ($612B market cap) as a low-volatility dividend grower with sales up 6.6% YoY to ~$25B last quarter and 64 consecutive years of dividend increases (67% payout growth over 10 years). It also flags UnitedHealth as having rebounded from a >50% drawdown tied to elevated claims costs and overspending/fraud, noting a current dividend yield of 2.26% and 271% dividend-per-share growth over 10 years. Finally, McKesson is positioned as a defensive healthcare supply-chain dividend compounder with a dividend-per-share up 193% over 10 years.

Analysis

This reads more like a positioning reminder than a catalyst. In a tape making new highs, healthcare defensives tend to lag because they lack the convexity and narrative torque that attract incremental risk capital; that makes the sector better suited as a volatility hedge than as a momentum allocation. Within the group, MCK is the cleanest “quality compounder” because its economics are tied to prescription volume and pricing pass-through, while JNJ is mostly a low-beta earnings stream and UNH is the only name with meaningful upside if utilization normalizes.

The second-order issue is valuation support: dividend growth alone is not enough if real yields stay elevated, because these stocks are competing with cash-like returns. For MCK, the biggest upside is not margin expansion but capital return plus steady healthcare inflation; for JNJ, upside is capped unless pipeline or medtech growth re-accelerates; for UNH, the stock can rerate sharply only if claims trends and pricing power improve together over the next 1-2 quarters. If those data points do not confirm, the rebound thesis remains fragile.

Contrarian takeaway: the market may be overpaying for “safety” in a risk-on environment. The better trade is selective defensiveness, not blanket ownership of all three names. UNH has the most asymmetric upside if the cost cycle turns, but it also has the highest headline and reimbursement risk; JNJ is the most durable but least likely to outperform; MCK sits in the middle with the best risk/reward for steady compounding.

Key Decisions for Investors

• Prefer MCK over JNJ for a 1-3 month healthcare allocation: long MCK / short JNJ in small size as a relative-value pair; thesis is better earnings sensitivity and capital-return support, with JNJ acting as the lower-beta funding leg.
• Do not chase UNH until the next claims-cost checkpoint; if medical cost trends fail to improve over the next quarter, the rebound narrative likely stalls. If already long, hedge with a collar rather than adding risk.
• Use XLV as a drawdown hedge only on risk-off spikes or VIX expansion, not after a strong market rally; healthcare defensives usually work best when the market starts pricing recession risk.
• For income-oriented accounts, JNJ is acceptable as a bond-proxy holding, but set expectations for muted relative performance unless rates fall or pipeline/margin re-acceleration shows up in earnings.